{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T19:10:07Z","timestamp":1793214607801,"version":"4.5.0"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,8,21]],"date-time":"2020-08-21T00:00:00Z","timestamp":1597968000000},"content-version":"am","delay-in-days":264,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100011944","name":"School of Public Health, University of California Berkeley","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011944","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001818","name":"Research to Prevent Blindness","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001818","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004286","name":"Santen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004286","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"publisher","award":["EY014943"],"award-info":[{"award-number":["EY014943"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007819","name":"Allergan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007819","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008556","name":"Paul MacKall and Evanina Bell MacKall Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008556","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000200","name":"United States Agency for International Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000200","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajo.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.ajo.2019.07.008","type":"journal-article","created":{"date-parts":[[2019,7,22]],"date-time":"2019-07-22T19:28:31Z","timestamp":1563823711000},"page":"68-75","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"special_numbering":"C","title":["Comparison Between Methotrexate and Mycophenolate Mofetil Monotherapy for the Control of Noninfectious Ocular Inflammatory Diseases"],"prefix":"10.1016","volume":"208","author":[{"given":"Sapna S.","family":"Gangaputra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig W.","family":"Newcomb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marshall M.","family":"Joffe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kurt","family":"Dreger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hosne","family":"Begum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pichaporn","family":"Artornsombudh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siddharth S.","family":"Pujari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ebenezer","family":"Daniel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Nida","family":"Sen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric B.","family":"Suhler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer E.","family":"Thorne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nirali P.","family":"Bhatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Stephen","family":"Foster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas A.","family":"Jabs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert B.","family":"Nussenblatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James T.","family":"Rosenbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace A.","family":"Levy-Clarke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John H.","family":"Kempen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajo.2019.07.008_bib1","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/S0002-9394(00)00659-0","article-title":"Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel","volume":"130","author":"Jabs","year":"2000","journal-title":"Am J Ophthalmol"},{"issue":"10","key":"10.1016\/j.ajo.2019.07.008_bib2","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1016\/j.ophtha.2011.07.027","article-title":"Randomized comparison of systemic anti-inflammatory therapy versus fluocinolone acetonide implant for intermediate, posterior, and panuveitis: the multicenter uveitis steroid treatment trial","volume":"118","author":"Kempen","year":"2011","journal-title":"Ophthalmology"},{"issue":"10","key":"10.1016\/j.ajo.2019.07.008_bib3","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1016\/j.ophtha.2015.06.042","volume":"122","author":"Kempen","year":"2015","journal-title":"Ophthalmology"},{"issue":"19","key":"10.1016\/j.ajo.2019.07.008_bib4","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1001\/jama.2017.5103","article-title":"Association between long-lasting intravitreous fluocinolone acetonide implant vs systemic anti-inflammatory therapy and visual acuity at 7 years among patients with intermediate, posterior, or panuveitis","volume":"317","author":"Kempen","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.ajo.2019.07.008_bib5","doi-asserted-by":"crossref","first-page":"b2480","DOI":"10.1136\/bmj.b2480","article-title":"Overall and cancer related mortality among patients with ocular inflammation treated with immunosuppressive drugs: retrospective cohort study","volume":"339","author":"Kempen","year":"2009","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.ajo.2019.07.008_bib6","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1167\/iovs.11-8259","article-title":"Associations among visual acuity and vision- and health-related quality of life among patients in the multicenter uveitis steroid treatment trial","volume":"53","author":"Frick","year":"2012","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"5","key":"10.1016\/j.ajo.2019.07.008_bib7","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1097\/00001648-200009000-00011","article-title":"Marginal structural models and causal inference in epidemiology","volume":"11","author":"Robins","year":"2000","journal-title":"Epidemiology"},{"issue":"5","key":"10.1016\/j.ajo.2019.07.008_bib8","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/00001648-200009000-00012","article-title":"Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men","volume":"11","author":"Hern\u00e1n","year":"2000","journal-title":"Epidemiology"},{"issue":"4","key":"10.1016\/j.ajo.2019.07.008_bib9","doi-asserted-by":"crossref","first-page":"197","DOI":"10.3109\/09286586.2013.792939","article-title":"Marginal structural models for comparing alternative treatment strategies in ophthalmology using observational data","volume":"20","author":"Joffe","year":"2013","journal-title":"Ophthalmic Epidemiol"},{"issue":"1","key":"10.1016\/j.ajo.2019.07.008_bib10","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ajo.2009.08.024","article-title":"Propensity score methods","volume":"149","author":"Rubin","year":"2010","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ajo.2019.07.008_bib11","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1080\/09286580701585892","article-title":"Methods for identifying long-term adverse effects of treatment in patients with eye diseases: the Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort Study","volume":"15","author":"Kempen","year":"2008","journal-title":"Ophthalmic Epidemiol"},{"issue":"11","key":"10.1016\/j.ajo.2019.07.008_bib12","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1016\/j.ophtha.2009.04.020","article-title":"Systemic Immunosuppressive Therapy for Eye Diseases Cohort Study. Methotrexate for ocular inflammatory diseases","volume":"116","author":"Gangaputra","year":"2009","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1016\/j.ajo.2019.07.008_bib13","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.ajo.2009.09.026","article-title":"Mycophenolate mofetil for ocular inflammation","volume":"149","author":"Daniel","year":"2010","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ajo.2019.07.008_bib14","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"issue":"1","key":"10.1016\/j.ajo.2019.07.008_bib15","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s12348-011-0047-5","article-title":"Corticosteroid-sparing therapy: practice patterns among uveitis specialists","volume":"2","author":"Esterberg","year":"2012","journal-title":"J Ophthalmic Inflamm Infect"},{"issue":"1","key":"10.1016\/j.ajo.2019.07.008_bib16","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1080\/09286586.2016.1255764","article-title":"A Bayesian analysis of a randomized clinical trial comparing antimetabolite therapies for non-infectious uveitis","volume":"24","author":"Browne","year":"2017","journal-title":"Ophthalmic Epidemiol"},{"issue":"10","key":"10.1016\/j.ajo.2019.07.008_bib17","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1016\/j.ophtha.2014.04.023","article-title":"A randomized clinical trial comparing methotrexate and mycophenolate mofetil for noninfectious uveitis","volume":"121","author":"Rathinam","year":"2014","journal-title":"Ophthalmology"},{"issue":"10","key":"10.1016\/j.ajo.2019.07.008_bib18","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1016\/j.ophtha.2008.04.026","article-title":"Comparison of antimetabolite drugs as corticosteroid-sparing therapy for noninfectious ocular inflammation","volume":"115","author":"Galor","year":"2008","journal-title":"Ophthalmology"},{"issue":"12","key":"10.1016\/j.ajo.2019.07.008_bib19","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1136\/bjo.2006.097998","article-title":"Retention time for corticosteroid-sparing systemic immunosuppressive agents in patients with inflammatory eye disease","volume":"90","author":"Baker","year":"2006","journal-title":"Br J Ophthalmol"},{"issue":"3","key":"10.1016\/j.ajo.2019.07.008_bib20","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ajo.2005.03.057","article-title":"Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop","volume":"140","author":"Jabs","year":"2005","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ajo.2019.07.008_bib21","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1002\/sim.4780080608","article-title":"The control of confounding by intermediate variables","volume":"8","author":"Robins","year":"1989","journal-title":"Stat Med"},{"key":"10.1016\/j.ajo.2019.07.008_bib22","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/00001648-199207000-00007","article-title":"G-estimation of the effect of prophylaxis therapy for Pneumocystis carinii pneumonia on the survival of AIDS patients","volume":"3","author":"Robins","year":"1992","journal-title":"Epidemiology"}],"container-title":["American Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939419303319?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939419303319?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T10:41:41Z","timestamp":1762080101000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002939419303319"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":22,"alternative-id":["S0002939419303319"],"URL":"https:\/\/doi.org\/10.1016\/j.ajo.2019.07.008","relation":{},"ISSN":["0002-9394"],"issn-type":[{"value":"0002-9394","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison Between Methotrexate and Mycophenolate Mofetil Monotherapy for the Control of Noninfectious Ocular Inflammatory Diseases","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajo.2019.07.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}